Cameron Turtle - 02 Jan 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Executive Officer, Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
02 Jan 2026
Net transactions value
-$460,134
Form type
4
Filing time
06 Jan 2026, 21:36:32 UTC
Previous filing
03 Dec 2025
Next filing
13 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Turtle Cameron Chief Executive Officer, Director 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM /s/ Heidy King-Jones, as Attorney-in-Fact 06 Jan 2026 0001758363

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRE Common Stock Sale $387,243 -12,709 -1.9% $30.47 674,198 02 Jan 2026 Direct F1, F2, F3
transaction SYRE Common Stock Sale $69,652 -2,191 -0.32% $31.79 672,007 02 Jan 2026 Direct F1, F3, F4
transaction SYRE Common Stock Sale $3,239 -100 -0.01% $32.39 671,907 02 Jan 2026 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $31.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.
F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.29 to $32.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.